Oncology drug research and development has advanced dramatically in recent times, and IRBM is proud to have played its part. Two medicines which we helped to develop are now on the market: ZEJULA®, for ovarian cancer, and ZOLINZA®, for a skin-affecting lymphoma.
We are now entering a new and exciting era of drug discovery where the only limit is our imagination. Precision medicines, immune checkpoint inhibitors, cell therapies, protein degraders, antibody-drug conjugates (ADCs), peptide therapeutics, and radiotheranostics, are just a few examples of the many drug modalities that have been added to the world’s armory against cancer. These innovations are transforming the lives of thousands of patients and we, at IRBM, are committed to pave the way to a new wave of cancer therapeutics.
We are proud of our partnerships with world-renowned organizations devoted to cancer patient care including MD Anderson Cancer Center, and to have been selected by the NIH as a member of the NCI Experimental Therapeutics (NExT) Program’s Chemical Biology Consortium (CBC) to help address unmet needs in therapeutic oncology
What sets us apart from other CROs is the extensive experience our team of scientists has built across the breadth of oncology drug discovery and translational research, to advance many clinical candidates into oncology trials. This unrivalled background, coupled with our passion to deliver innovative therapies that will treat a wide range of patients including those with rare, and often neglected, cancers, makes us your partner of choice.
We cover the range of oncology drug discovery phases from target validation through to candidate nomination. In the tables below we list a selection of the many capabilities we can apply to oncology programs.
Talk to us to help transform your ideas into the oncology medicines of the future.